(NYSE: RDY) Dr Reddys Laboratories's forecast annual revenue growth rate of 3.48% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.14%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Dr Reddys Laboratories's revenue in 2025 is $3,785,730,898.On average, 3 Wall Street analysts forecast RDY's revenue for 2026 to be $3,437,558,068,591, with the lowest RDY revenue forecast at $3,364,974,637,577, and the highest RDY revenue forecast at $3,544,649,566,769. On average, 3 Wall Street analysts forecast RDY's revenue for 2027 to be $3,371,174,640,939, with the lowest RDY revenue forecast at $3,299,027,630,081, and the highest RDY revenue forecast at $3,422,677,226,067.
In 2028, RDY is forecast to generate $3,559,569,628,695 in revenue, with the lowest revenue forecast at $3,401,899,287,478 and the highest revenue forecast at $3,717,239,969,912.